Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolcapone as Genotype-Based Cognitive Enhancer in Schizophrenia (rs4680)
2024-511433-35-00Phase 2Completed
- Sponsor
- Clínica Universidad de Navarra
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of tolcapone in schizophrenia, sponsored by Clínica Universidad de Navarra. Primary endpoints: Cognitive performance (DPX and modified MATRICS) and Brain activation during fMRI (BOLD response). Started May 2024; status: completed.
02
Drugs
tolcapone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2024-511433-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511433-35-00.